Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Clinical Research

Resistin/uric acid index as a marker of metabolic syndrome in females with obesity

International Journal of Obesity volume 47, pages 393–398 (2023)Cite this article

Subjects

Abstract

Background

The resistin/uric index has been considered a prognostic factor for identifying young people with obesity. Obesity and Metabolic Syndrome (MS) are an important health problem in females.

Aims

The objective of this work was to evaluate the relationship of resistin/acid uric index with Metabolic Syndrome on Caucasian females with obesity.

Methods

We conducted a cross sectional study in 571 females with obesity. Measurements of anthropometric parameters, blood pressure, fasting blood glucose, insulin concentration, insulin resistance (HOMA-IR), lipid profile, C reactive protein, uric acid, resistin and prevalence of Metabolic Syndrome were determined. The resistin/uric acid index was calculated.

Results

In total, 249 subjects had MS (43.6%). We detected higher levels in the following parameters (Delta; p values); waist circumference (3.1 ± 0.5 cm; p = 0.04), systolic blood pressure (5.3 ± 3.6 mmHg; p = 0.01), diastolic blood pressure (2.3 ± 0.4 mmHg; p = 0.02), glucose levels (7.5 ± 0.9 mg/dL; p = 0.01), insulin levels (2.5 ± 0.3 UI/L; p = 0.02), HOMA-IR (0.7 ± 0.2 units; p = 0.03), uric acid levels (0.9 ± 0.2 mg/dl; p = 0.01), resistin levels (4.1 ± 0.4 ng/dl; p = 0.01) and resistin/uric acid index (0.61 ± 0.01 mg/dl; p = 0.02) in subjects of the high resistin/uric acid index group than low index group. Logistic regression analysis reported a high percentage of hyperglycemia (OR = 1.77, 95% CI = 1.10–2.92; p = 0.02), hypertension (OR = 1.91, 95% CI = 1.36–3.01; p = 0.01), central obesity (OR = 1.48, 95% CI = 1.15–1.84; p = 0.03) and metabolic syndrome percentage (OR = 1.71, 95% CI = 1.22–2.69; p = 0.02) in high resistin/uric acid index group.

Conclusions

Resistin/uric acid index is related with Metabolic syndrome (MS) risk and criteria of it in a population of Caucasian females with obesity and this index is a correlated with glucose levels, insulin levels and insulin resistance (HOMA-IR).

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Data availability

All data generated or analyzed during this study are included in this article. Further enquiries can be directed to the corresponding author.

References

  1. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011;377:557–67.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gutiérrez-Fisac JL, Guallar-Castillón P, León-Muñoz LM, Graciani A, Banegas JR, Rodríguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study. Obes Rev. 2012;13:388–92.

    Article  PubMed  Google Scholar 

  3. Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148:852–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Pagano C, Marin O, Calcagno A, Schiappelli P, Pilon C, Milan G, et al. Increased serum resistin in adults with Prader Willi syndrome is related to obesity and not to insulin resistance. J Clin Endocrinol Metab. 2005;90:4335–40.

    Article  CAS  PubMed  Google Scholar 

  5. Burnett MS, Devaney JM, Adenika RJ, Lindsay R, Howard BV. Cross-sectional associations of resistin, coronary heart disease and insulin resistance. J Clin Endocr Metab. 2006;91:64–68.

    Article  CAS  PubMed  Google Scholar 

  6. Zou CC, Liang L, Hong F, Fu JF, Zhao ZY. Serum adiponectin, resistin levels and non alcoholic fatty liver disease in obese children. Endocrine J. 2005;52:519–24.

    Article  CAS  Google Scholar 

  7. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA. Activation of SOCS-3 by resistin. Mol Cell Biol. 2005;25:1569–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Hsia SH, Chou IJ, Kuo CF, See LC, Huang JL, Yu KH, et al. Survival impact of serum uric acid levels in children and adolescents. Rheumatol Int. 2013;33:2797–802.

    Article  CAS  PubMed  Google Scholar 

  9. Safiri S, Qorbani M, Heshmat R, Tajbakhsh R, Eslami Shahr Babaki A, Djalalinia S, et al. Association of serum uric acid with cardiometabolic risk factors and metabolic syndrome in Iranian Adolescents: the CASPIAN-III Study. Iran J Kidney Dis. 2016;10:126–34.

    PubMed  Google Scholar 

  10. Sautin YY, Nakagawa T, Zharikov S, Johnson RJ. Adverse effects of the classic antioxidant uric acid in adipocytes: NADPH oxidase-mediated oxidative/nitrosative stress. Am J Physiol Cell Physiol. 2007;293:584–96.

    Article  Google Scholar 

  11. Johnson RJ, Lanaspa MA, Gaucher EA. Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. Semin Nephrol. 2011;31:394–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486–97.

  13. de Luis DA, Izaola O, Primo D, Aller R. Relation of a variant in adiponectin gene (rs266729) with metabolic syndrome and diabetes mellitus type 2 in adult obese subjects. Eur Rev Med Pharmacol Sci. 2020;24:10646–52.

    PubMed  Google Scholar 

  14. Sayeed G, Varghese SS. Association between periodontitis and metabolic syndrome in females: a systematic review and meta-analysis. J Int Soc Prev Community Dent. 2021;11:609–25.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Zurita-Cruz J, Villasis-Keever M, Manuel-Apolinar L, Damasio-Santana L, Wakida-Kusunoki GH, Padilla-Rojas M, et al. Resistin/uric acid index as a prognostic factor in adolescents with obesity after lifestyle intervention. J Pediatr. 2020;219:38–42.

    Article  CAS  PubMed  Google Scholar 

  16. Lukaski H, Johson PE. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. Am J Clin Nutr. 1985;41:810–7.

    Article  CAS  PubMed  Google Scholar 

  17. Friedewald WT, Levy RJ, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499–502.

    Article  CAS  PubMed  Google Scholar 

  18. Mathews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF. Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–4.

    Article  Google Scholar 

  19. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med. 2004;1:e45.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Aquilante CL, Kosmiski LA, Knutsen SD, Zineh I. Relationship between plasma resistin concentrations, inflammatory chemokines, and components of the metabolic syndrome in adults. Metabolism. 2008;57:494–501.

    Article  CAS  PubMed  Google Scholar 

  21. Kim KH, Zhao L, Moon Y, Kang C, Sul HS. Dominant inhibitory adipocytespecific secretory factor (ADSF)/resistin enhances adipogenesis and improves insulin sensitivity. Proc Natl Acad Sci USA. 2004;101:6780–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Gupta V, Singh A, Gupta V, Kumar S, Srivastava N, Jafar T, et al. Association of circulating resistin with metabolic risk factors in Indian females having metabolic syndrome. Toxicol Int. 2011;18:168.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Bednarska-Makaruk M, Graban A, Wiśniewska A, Łojkowska W, Bochyńska A, Gugała-Iwaniuk M, et al. Association of adiponectin, leptin and resistin with inflammatory markers and obesity in dementia. Biogerontology. 2017;18:561–80.

  24. Thomopoulos C, Daskalaki M, Papazachou O, Rodolakis N, Bratsas A, Papadopoulos D, et al. Association of resistin and adiponectin with different clinical blood pressure phenotypes. J Hum Hyperten. 2011;25:38.

    Article  CAS  Google Scholar 

  25. Teng X, Li D, Champion HC, Johns RA. FIZZ1/RELMa, a novel hypoxia-induced mitogenic factor in lung with vasoconstrictive and angiogenic properties. Circul Res. 2003;92:1065–7.

    Article  CAS  Google Scholar 

  26. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal– regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004;110:3335–40.

    Article  CAS  PubMed  Google Scholar 

  27. Singh AK, Tiwari S, Gupta A, Shukla KK, Chhabra KG, Pandey A, et al. Association of resistin with insulin resistance and factors of metabolic syndrome in north Indians. Indian J Clin Biochem. 2015;30:255–62.

    Article  CAS  PubMed  Google Scholar 

  28. de Luis D, Sagrado MG, Conde R, Aller R, Izaola O, Primo D. Lack of association of serum resistin levels with metabolic syndrome criteria in obese female patients. Clin Biochem. 2011;44:1280–3.

    Article  PubMed  Google Scholar 

  29. Nakanishi N, Suzuki K, Kawashimo H, Nakamura K, Tatara K. Serum uric acid: correlation with biological, clinical and behavioral factors in Japanese men. J Epidemiol. 1999;9:99–106.

    Article  CAS  PubMed  Google Scholar 

  30. Russo C, Olivieri O, Girelli D, Guarini P, Corrocher R. Relationships between serum uric acid and lipids in healthy subjects. Prev Med. 1996;25:611–616.

    Article  CAS  PubMed  Google Scholar 

  31. Ramsay LE. Hyperuricaemia in hypertension: role of alcohol. BrMed J. 1979;1:653–4.

    CAS  Google Scholar 

  32. Alper AB Jr., Chen W, Yau L, Srinivasan SR, Berenson GS, Hamm LL. Childhood uric acid predicts adult blood pressure: The Bogalusa Heart Study. Hypertension. 2005;45:34–38.

    Article  CAS  PubMed  Google Scholar 

  33. Krishnan E, Pandya BJ, Chung L, Hariri A, Dabbous O. Hyperuricemia in young adults and risk of insulin resistance, prediabetes, and diabetes: A 15-year follow-up study. Am J Epidemiol. 2012;176:108–116.

    Article  PubMed  Google Scholar 

  34. Johnson RJ, Lanaspa MA, Gaucher EA. Uric acid: a danger signal from the RNA world that may have a role in the epidemic of obesity, metabolic syndrome, and cardiorenal disease: evolutionary considerations. Elsevier: Seminars Nephrol. 2011;16:234–54.

    Google Scholar 

  35. Matsuura F, Yamashita S, Nakamura T, Nishida M, Nozaki S, Funahashi T, et al. Effect of visceral fat accumulation on uric acid metabolism in male obese subjects: Visceral fat obesity is linked more closely to overproduction of uric acid than subcutaneous fat obesity. Metabolism. 1998;47:929–33.

    Article  CAS  PubMed  Google Scholar 

  36. Goli P, Riahi R, Daniali SS, Pourmirzaei M, Kelishadi R. Association of serum uric acid concentration with components of pediatric metabolic syndrome: A systematic review and meta-analysis. J Res Med Sci. 2020;13:25–43.

    Google Scholar 

  37. Kuwabara M, Borghi C, Cicero AFG, Hisatome I, Niwa K, Ohno M, et al. Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: a five-year cohort study in Japan. Int J Cardiol. 2018;261:183–8.

    Article  PubMed  Google Scholar 

  38. Choi HK, Ford ES. Prevalence of the metabolic syndrome in individuals with hyperuricemia. Am J Med. 2007;120:442–447.

    Article  PubMed  Google Scholar 

  39. Bulum T, Tomić M, Vučković-Rebrina S, Roso V, Vučić Lovrenčić M, Duvnjak L. Preserved C-peptide secretion in patients with type 1 diabetes and incipient chronic complications is associated with lower serum resistin and higher uric acid levels. J Diabetes Metab Disord. 2020;19:1185–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. de Luis D, Aller R, Izaola O, Primo D. Role of the rs10401670 variant in the resistin gene on the metabolic response after weight loss secondary to a high-fat hypocaloric diet with a Mediterranean pattern. J Hum Nutr Diet. 2022;35:722–30. Aug

    Article  PubMed  Google Scholar 

  41. de Luis DA, Izaola O, Primo D, Aller R. Effect of the rs1862513 variant of resistin gene on insulin resistance and resistin levels after two hypocaloric diets with different fat distribution in subjects with obesity. Eur Rev Med Pharmacol Sci. 2018;22:3865–72.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology and Nutrition Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain

    David Primo & Olatz Izaola

  2. Investigation Centre on Endocrinology and Nutrition (IEN), University of Valladolid, Valladolid, Spain

    David Primo, Olatz Izaola & Daniel de Luis

Authors
  1. David Primo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Olatz Izaola
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel de Luis
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

DdeL designed the study an wrote the article. OI, realized nutritional evaluation. DP and DdeL realized biochemical evaluation.

Corresponding author

Correspondence to Daniel de Luis.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics statement

This study protocol was reviewed and approved by [HCVUA Commitee], approval number [No 6/2018] Written Informed consent was obtained from all individual participants included in the study.

Consent to participate statement

Signed informed consent was otained in all participants. This research comply with the guidelines for human studies in accordance with the World Medical Association Declaration of Helsinki.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Primo, D., Izaola, O. & de Luis, D. Resistin/uric acid index as a marker of metabolic syndrome in females with obesity. Int J Obes 47, 393–398 (2023). https://doi.org/10.1038/s41366-023-01287-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41366-023-01287-4

Search

Advanced search

Quick links